Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.

Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Smith GE, Frieman MB.

Vaccine. 2014 May 30;32(26):3169-3174. doi: 10.1016/j.vaccine.2014.04.016. Epub 2014 Apr 13.

2.
3.

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD.

J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.

4.

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.

Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A.

Vaccine. 2014 Oct 14;32(45):5975-82. doi: 10.1016/j.vaccine.2014.08.058. Epub 2014 Sep 3.

PMID:
25192975
5.

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ.

J Virol. 2017 Jan 3;91(2). pii: e02040-16. doi: 10.1128/JVI.02040-16. Print 2017 Jan 15.

6.

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.

Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CK, Li F, Zhou Y, Jiang S, Du L.

Vaccine. 2014 Oct 21;32(46):6170-6176. doi: 10.1016/j.vaccine.2014.08.086. Epub 2014 Sep 19.

7.

Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N.

J Virol. 2015 Mar;89(6):2995-3007. doi: 10.1128/JVI.02980-14. Epub 2014 Dec 17.

8.

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.

Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G.

Vaccine. 2011 Sep 2;29(38):6606-13. doi: 10.1016/j.vaccine.2011.06.111. Epub 2011 Jul 14.

9.

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.

Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD, Haagmans BL, Sutter G.

J Virol. 2013 Nov;87(21):11950-4. doi: 10.1128/JVI.01672-13. Epub 2013 Aug 28.

10.

Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.

Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA.

J Virol. 2014 Dec;88(23):13769-80. doi: 10.1128/JVI.02232-14. Epub 2014 Sep 17.

11.

Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.

Choi J, Kim MG, Oh YK, Kim YB.

Expert Opin Ther Pat. 2017 Jun;27(6):721-731. doi: 10.1080/13543776.2017.1281248. Epub 2017 Jan 25. Review.

PMID:
28121202
12.

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.

Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G.

J Virol. 2015 Aug;89(16):8651-6. doi: 10.1128/JVI.00614-15. Epub 2015 May 27.

13.

Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.

Agnihothram S, Gopal R, Yount BL Jr, Donaldson EF, Menachery VD, Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS.

J Infect Dis. 2014 Apr 1;209(7):995-1006. doi: 10.1093/infdis/jit609. Epub 2013 Nov 18.

14.

Evaluation of candidate vaccine approaches for MERS-CoV.

Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS.

Nat Commun. 2015 Jul 28;6:7712. doi: 10.1038/ncomms8712.

15.

Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.

Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, Zhou Y, Jiang S.

J Virol. 2013 Sep;87(17):9939-42. doi: 10.1128/JVI.01048-13. Epub 2013 Jul 3. Erratum in: J Virol. 2013 Nov;87(21):11963.

16.
17.

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, Zhou Y, Perlman S, Jiang S, Du L.

Cell Mol Immunol. 2016 Mar;13(2):180-90. doi: 10.1038/cmi.2015.03. Epub 2015 Feb 2.

18.

A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant.

Agnihothram S, Yount BL Jr, Donaldson EF, Huynh J, Menachery VD, Gralinski LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL, Whitmore A, Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M, Denison MR, Baric RS.

MBio. 2014 Mar 25;5(2):e00047-14. doi: 10.1128/mBio.00047-14.

20.

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.

Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y.

Virol J. 2013 Aug 26;10:266. doi: 10.1186/1743-422X-10-266.

Supplemental Content

Support Center